Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

Rhea-AI Summary

Marinus Pharmaceuticals, Inc. (MRNS) plans to release its financial results for Q4 and FY 2020 on March 9, 2021, before the market opens. A conference call is scheduled for the same day at 8:30 AM ET to discuss these results and provide a business update. The company focuses on developing therapeutics for rare seizure disorders, with its lead product, Ganaxolone, proceeding through various clinical trials, including Phase 3 for status epilepticus and trials for CDKL5 deficiency disorder and tuberous sclerosis complex.

Positive

• Progress in clinical trials: Completed Phase 3 trial for CDKL5 deficiency.
• Ganaxolone development in IV and oral forms for broader patient access.

Negative

• None.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it plans to release financial results for the fourth quarter and fiscal year ended December 31, 2020 before the market opens on March 9, 2021. The company will host a conference call at 8:30am Eastern Time on March 9, 2021 to provide a business update and discuss the financial results.

Tuesday, March 9: 8:30 AM Eastern Time
Domestic:			(833) 979-2765
International:			(343) 761-2590
Webcast:			https://event.on24.com/wcc/r/2948497/012AE4F51A475A8BDC3559C95635FBF2
Conference ID:			2673136

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company is conducting a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005209/en/

FAQ

What are the upcoming financial results release dates for Marinus Pharmaceuticals (MRNS)?

Marinus Pharmaceuticals (MRNS) will release its financial results for Q4 and FY 2020 on March 9, 2021.

When is the Marinus Pharmaceuticals conference call scheduled?

The conference call for Marinus Pharmaceuticals will occur on March 9, 2021, at 8:30 AM Eastern Time.

What is Ganaxolone and its significance for Marinus Pharmaceuticals?

Ganaxolone is a therapeutic being developed by Marinus Pharmaceuticals for treating rare seizure disorders and is currently undergoing various clinical trials.

What clinical trials is Marinus Pharmaceuticals currently conducting?

Marinus Pharmaceuticals is conducting a Phase 3 trial in status epilepticus, a Phase 2 trial in tuberous sclerosis complex, and a Phase 2 trial for PCDH19-related epilepsy.